Calliditas Therapeutics: China – score!
Research Note
2019-06-10
09:09
Calliditas today announced that they have entered into a license agreement with Everest Medicines to develop and commercialize Nefecon in Greater China and Singapore for IgA Nephropathy. We have not included any deal for Asia in our model and today’s news will have a positive effect on our valuation.
LS
Ludvig Svensson
Disclosures and disclaimers